Podcasts about biotech

Biotech is one of the few areas in investing where specialized knowledge may still generate persistent alpha. In this episode of Excess Returns, D.A. Wallach, venture capitalist and co-founder of Time BioVentures, joins us to explain how biotech investing works, why development-stage drug companies behave like portfolios of options, and why specialist investors play such a large role in this market. We also explore the cycles that have driven biotech performance, the impact of interest rates and capital flows, and how AI and global competition may reshape the industry in the years ahead.D.A. Wallach – Twitterhttps://x.com/DAWallachTopics covered include• Why biotech may be one of the last areas where specialist investors can generate persistent alpha• The “bag of options” framework for valuing development-stage biotech companies• How probabilities of drug success and clinical base rates drive biotech valuations• Why rising interest rates hit biotech stocks harder than many other sectors• How capital flows and investor narratives create boom-and-bust cycles in biotech• What happened to biotech during the pandemic surge and the post-COVID downturn• Why AI and tech narratives compete with biotech for investor attention• The role of specialist biotech hedge funds in the public markets• How large pharmaceutical companies drive returns through biotech acquisitions• Differences between biotech venture capital and traditional tech venture investing• How venture investors evaluate drug development programs and scientific evidence• Portfolio construction and diversification when investing in highly uncertain biotech companies• The emerging role of China in clinical trials and global drug development• Whether AI can improve drug discovery, clinical trials, and pharmaceutical R&D productivity• Why investors should avoid rigid value vs growth ideologies and stay adaptableTimestamps00:00 Why biotech investing requires specialized knowledge01:40 Is biotech one of the last places for persistent active alpha?02:45 The “bag of options” model for valuing biotech companies05:00 Drug development phases and probabilities of success07:00 Using base rates to estimate clinical trial success09:20 Estimating total addressable markets for new drugs11:10 Why rising interest rates hurt biotech valuations13:00 Capital flows and why biotech underperformed in recent years15:30 The biotech boom and bust around the COVID pandemic18:00 How AI and tech compete with biotech for investor capital22:20 The role of specialist biotech hedge funds24:00 How pharmaceutical acquisitions drive biotech returns25:20 How biotech venture capital differs from tech VC30:50 Why biotech investors must evaluate complex scientific data34:20 Where AI may improve drug discovery and R&D productivity42:00 Portfolio construction and diversification in biotech venture investing44:30 Volatility, valuation marks, and private market pricing48:00 Managing risk across different drug technologies and disease areas49:30 Why China is becoming important for clinical trials53:00 Why biotech investing must be viewed as a global industry54:30 The importance of flexibility between value and growth investing58:50 Will investing become more systematic and quantitative over time

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Joerg Ahlgrimm, CEO SK pharmteco.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Joerg, covering:   His journey from East Germany to leading global manufacturing organisations. How building and integrating acquired CDMO relationships ultimately led him to Lonza, where he helped scale the manufacturing network from fifteen to thirty five sites worldwide. What he learned about the “sticky” nature of the CDMO business, and the unforgiving reality of being a CDMO partner when execution does not go to plan. The leap from the scale and structure of Lonza in Basel to becoming employee number four at a CDMO start up in Philadelphia. Why his vision for a small molecule CDMO is to be easy to work with and present across the key global manufacturing regions. Why, despite the rise of blockbuster GLP one therapies, he believes the future lies in small volume, highly targeted, and complex to manufacture personalised medicines.   Joerg Ahlgrimm is a global operations and supply chain executive with more than 25 years of leadership experience across the biotech, pharmaceutical, vaccines, and medical device industries. As CEO of SK pharmteco, he leads the company's strategic growth and operational excellence across its global manufacturing network.   Prior to SK pharmteco, Joerg served as Head of Global Operations, Pharma and Biotech at Lonza AG, where he oversaw 37 sites worldwide. Earlier, he led the manufacturing network for Baxter Bioscience/Baxalta, managing a broad global footprint and extensive CMO operations.   Driven by a passion for advancing patient care, Joerg is recognized for building high-performing teams and navigating complex global supply chains. He was recently appointed to the inaugural Strategic Advisory Board of BioPhorum, joining senior industry leaders to help shape the future of pharmaceutical manufacturing and supply chain resilience.   Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Protein engineering has traditionally been slow, expensive, and stuck in trial-and-error mode—but AI is changing everything. In this episode, we sit down with Elise De Reus, co-founder of Cradle Bio, to explore how generative AI is revolutionizing the way scientists design proteins for medicines, enzymes, and sustainable materials. Elise shares her journey from studying fungi and building high-throughput strain engineering systems at companies like Zymergen and Perfect Day, to creating an AI-powered platform that helps R&D teams generate better protein variants in less time and at lower cost. We discuss the massive design space of proteins, the role of machine learning in navigating that complexity, how Cradle balances computational predictions with biological reality, and what it will take for the bioeconomy to reach its trillion-dollar potential. Whether you're in pharma, industrial biotech, or just curious about the future of biology as a design problem, this conversation offers a fascinating look at how AI is becoming an essential tool for engineering the building blocks of life.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - The AI Revolution Meets Biology(00:01:00) - Why Erum Switched from ChatGPT to Claude (And What It Means for AI)(00:03:00) - Lab-Grown Meat Just Got Real: The Breakthrough That Changes Everything(00:06:00) - The Roadmap to a Trillion-Dollar Bioeconomy: Inside the AB4S Report(00:08:00) - Proteins 101: The Molecular Machines Running Your Life(00:10:00) - From Studying Fungi to Building AI Tools: Elise De Reus's Origin Story(00:12:00) - Inside Cradle Bio: The AI Studio Transforming How Scientists Design Proteins(00:15:00) - The "Short, Fat Data" Problem: Why Protein Engineering Needs Different AI(00:18:00) - Finding Needles in Infinite Haystacks: How Generative AI Navigates Protein Space(00:23:00) - When AI Is Confident But Wrong: Balancing Predictions with Biological Reality(00:27:00) - Speed vs. Caution: Why Pharma and Industrial Biotech Innovate Differently(00:30:00) - The $500 Billion Question: What's Really Blocking the Bioeconomy?(00:35:00) - Success Stories: How AI Unstuck Projects That Were Going Nowhere(00:38:00) - Sequence vs. Structure: Which AI Models Win at Protein Design?(00:41:00) - The Future Is Here: Better Data, Faster DNA Assembly, and Smarter Tools(00:43:00) - Quick Fire: Elise's Hot Takes on Biotech's Biggest Questions(00:47:00) - Biology as a Design Problem: Why This Changes EverythingLinks and Resources:CradleTurning lab-grown yeast into edible scaffoldingSynBioBeta Pass - Discount code: Grow Everything 166. The Great Reformulation: Joshua Lachter Rethinks How We Make Everything at ScaleTopics Covered:protein design, protein engineering, biotech, lab automation, biomanufacturing. synthetic biology, AI drug discovery, directed evolution, biologics, computational biology, enzyme optimizationHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

Science likes to call itself a meritocracy. Angela Anderson and Brandi Mattson know better. Both served as editors at elite journals (Cell and Neuron), where a single decision could determine who gets tenure, funding, or obscurity. They watched brilliant data get filtered out because the authors did not know the unwritten rules controlled by 5 dominant publishing houses with profit margins higher than Google.In 2020, amid pandemic shutdowns and national reckoning over racial injustice, they co-founded a nonprofit to expose that hidden curriculum. Through the JEDI program, they provide 10 hours of free editorial consulting to scientists who lack access to elite networks. In 1 year alone, 25 awards helped researchers salvage canceled grants, secure NSF career funding, and rebuild careers derailed by rejection.This episode pulls back the curtain on the multibillion dollar publishing engine that profits from taxpayer funded science and reveals who gets heard, who gets sidelined, and how insiders are choosing to redistribute power.RELATED LINKSAngela AndersonBrandy MattsonLife Science EditorsLife Science Editors FoundationCellNeuronNational Science FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Kurt: Thinking outside the box.Providing clean water to people in need is one of the most impactful ways to change lives. In this episode of Superpowers for Good, Kurt Avery, the founder and president of Sawyer Products, shared how his company is addressing two of the world's deadliest problems: unsafe drinking water and mosquito-borne illnesses. With innovations rooted in simplicity, affordability, and durability, Sawyer is transforming villages, saving lives, and improving livelihoods.Kurt explained that their life-changing water filters originated from kidney dialysis technology. “If you can clean blood, you can clean water,” he said. The filters are small, portable, and capable of removing bacteria and other harmful contaminants, making any water source drinkable. “We don't care if the cows are pooping in it or not. We just don't care. We'll make it drinkable,” Kurt assured.Sawyer's filters have already improved life for over 40 million people worldwide, with a one-time investment of as little as $0.30 per person providing clean water for up to 10 years. “Within weeks, people aren't sick. Within months, they're starting to shut down medical clinics because there aren't enough sick people,” Kurt said, emphasizing the profound transformation that access to clean water creates.Beyond water, Sawyer's insect repellents, including a new clothing treatment, are making strides in fighting malaria. A recent study published in the New England Journal of Medicine showed that using Sawyer's treated baby wraps reduced malaria rates in children under two by 57%. Kurt expressed optimism that this could climb to 90% with further development.What's most inspiring about Kurt's work is his commitment to reaching the people who need it most. Sawyer's products have been staples in disaster relief efforts worldwide, from earthquakes to hurricanes, where they provide immediate, life-saving access to clean water.As Kurt put it, “Half the world dies of mosquito bites or bad water. And I'm sitting there going, we've got the two solutions. Let's do this.”Sawyer is now at a pivotal moment, scaling its operations to help millions more. With their new tap filter technology and a goal to impact 40 million lives annually, Kurt and his team are inviting others to join their mission. “$0.30 a person. That's pretty good for 10 years,” Kurt said, highlighting the incredible value of their solutions.By leveraging innovative technology and a passion for doing good, Kurt Avery and Sawyer Products are demonstrating how business can create profound global impact.tl;dr:Kurt Avery shared how Sawyer Products provides life-saving clean water and mosquito repellent solutions worldwide.Sawyer's filters, derived from kidney dialysis technology, offer clean water for as little as $0.30 per person.Sawyer's insect repellents, including baby wraps, significantly reduce malaria in vulnerable populations.Kurt's bold “Why not?” mindset helped make Sawyer a leader in disaster relief and global health.Sawyer is scaling to impact 40 million lives annually, inviting others to support their mission.How to Develop Thinking Outside the Box As a SuperpowerKurt describes his superpower as the ability to think without boundaries, summarizing it with the mantra “Why not?” He explained, “I've never known where the box is,” attributing this mindset to his faith and belief in taking bold action. Kurt emphasized that once a solid plan is in place, there's no reason to hold back. “Why not do something to change the world?” he asked, encouraging others to embrace this fearless approach to problem-solving.When Iraq invaded Kuwait during the Gulf War, Kurt's company had just entered the sunscreen market. Despite hand-filling only 2,000 bottles per week, they boldly bid on a military contract requiring 200,000 bottles weekly. Against all odds, they secured the contract, scaled production, and delivered 6.2 million bottles. Their success hinged on Kurt's decision to send just two cases of their product to stores, meeting a critical contract requirement for commercial availability. When an inspector verified their status at a local store, the deal was sealed—a perfect example of Kurt's “Why not?” philosophy in action.Tips for Developing the Superpower:Adopt a “Why Not?” Mindset: Challenge assumptions and ask why something can't be done.Have a Solid Plan: Ensure your ideas are backed by thorough preparation and practical strategies.Take Calculated Risks: Trust your instincts and act boldly when opportunities arise.Embrace Failure as Part of Growth: Focus on learning from setbacks rather than fearing them.By following Kurt's example and advice, you can make thinking outside the box a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Invest in Ending Organ Shortages!Guest ProfileKurt Avery (he/him):Founder, Owner, President, Sawyer ProductsAbout Sawyer Products: Point of use water filters and insect repellents. State of the art technology.Website: sawyer.comCompany Facebook Page: facebook.com/people/Sawyer-Products/61563796295518/ Company Instagram Handle: @sawyerproducts Biographical Information: Kurt Avery is the founder and president of Sawyer Products, a company at the forefront of innovation in outdoor protection and humanitarian aid. With a background in marketing for Fortune 500 companies and an MBA from Northwestern University's Kellogg School of Management, Kurt launched Sawyer with a mission to develop practical, life-saving solutions—most notably in water filtration and insect repellents. Under his leadership, the company has grown into a global force, serving both outdoor enthusiasts and vulnerable communities around the world.Since 2008, Sawyer has donated over 90% of its profits annually, partnering with more than 140 nonprofits across 80+ countries and improving the lives of over 28 million people. Their clean-water initiatives have dramatically reduced waterborne diseases and improved health outcomes in underserved communities worldwide. Kurt's approach to business is deeply rooted in purpose, faith, and impact—a philosophy he shares in his book, Sawyer Think: How a Small Company Disrupts Markets and Changes the World.Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include rHealth, and Frontier Bio. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Superpowers for Good Live Pitch – Private Investor Session: Immediately following the March 17, 2026, live broadcast at 8 PM ET / 5 PM PT, investors are invited to join an exclusive private Zoom session to engage directly with the presenting founders—BRG Therapeutics (Dale Walker), GigaWatt (Deep Patel), My Diabetes Health (Dr. Prem Sahasranam), and rHEALTH (Eugene Chan). In this dedicated off-air environment, participants can ask deeper questions about strategy, traction, deal terms, and impact while exploring their active Regulation Crowdfunding campaigns in real time. Watch the live pitches on Roku, Amazon Fire TV, LG Smart TVs via e360tv, LinkedIn, YouTube, or Facebook—then continue the conversation in the private investor session where capital and clarity come together. Register free to get access to both events.SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on March 17th at 1:30 PM ET/10:30 AM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!SuperCrowdHour March: This month, Devin Thorpe will explore how investors can align profit with purpose in a powerful session titled “Why You Should Make Money with Impact Crowdfunding.” As CEO and Founder of The Super Crowd, Inc., Devin will share practical insights on generating financial returns while driving measurable social and environmental impact through regulated investment crowdfunding. Register free to get all the details. March 18th at Noon ET/9:00 PT.SuperCrowd26 featuring PurposeBuilt100™: This August 25–27, founders, investors, and ecosystem leaders will gather for a three-day, broadcast-quality global experience focused on disciplined capital formation, regulated investment crowdfunding, and purpose-driven growth. We're bringing together leading voices in impact investing, compliance, digital marketing, and circular economy innovation to deliver practical frameworks, real-world case studies, and actionable strategies. The event culminates in the PurposeBuilt100™ Showcase, recognizing 100 of the fastest-growing purpose-driven companies in the U.S. Register now to secure your seat and get all the details. August 25–27, streaming worldwide.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Nominate your MedTech, BioTech or Life Sciences company for the prestigious TAG Awards. The deadline is quickly approaching! Apply before March 13! Use the discount code SUPERPOWER to save 20%!If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

For more thoughts, clips, and updates, follow Avetis Antaplyan on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/avetisantaplyan⁠⁠⁠⁠In this episode of The Tech Leader's Playbook, Avetis Antaplyan sits down with Alok Tayi, a Harvard-trained scientist, repeat tech founder, and the founder of Vibe Bio. Alok shares his journey from academia and engineering into entrepreneurship, where he built multiple pharmaceutical software companies collectively worth nearly $1 billion before launching Vibe Bio with a deeply personal mission. After his daughter was born with two rare diseases that had no available treatments, Alok turned his attention to one of biotech's most overlooked challenges: accelerating innovation for rare disease patients.The conversation explores how AI is changing drug discovery, why rare disease innovation has historically been underfunded, and how new tools, data, and regulatory pathways are creating fresh opportunities for founders and investors alike. Alok explains how Vibe Bio uses proprietary AI to evaluate drug programs, support pharma decision-making, and guide venture investments into high-potential therapeutics. He also shares hard-won lessons on leadership, mission-driven company building, culture, and the importance of staying obsessed with the problem while remaining flexible on tactics. This episode is a thoughtful look at the intersection of science, entrepreneurship, capital, and meaningful impact.TakeawaysIntro to Alok Tayi and the mission behind Vibe BioFrom scientist to serial founder in life sciences softwareHow Alok's daughter's diagnosis changed his life and careerLeadership lessons from scaling companies at different stagesWhat Vibe Bio actually does and how its AI worksWhy biotech and pharma are harder than most founders expectBalancing regulation, speed, and commercial realityWhy rare disease communities have been historically overlookedWhy rare disease innovation may become more viable nowWhy non-scientists can still play a major role in biotechCapital efficiency, biotech cycles, and the real funding questionWhy AI is an accelerant for biotech, not a replacementThe rise of parent-led and unconventional biotech foundersVibe Bio's AI platform versus its venture fundPlatform companies vs. individual therapy companiesHow AI-driven evaluation changes therapeutic investingAlok's biggest business and culture lessons as a founderBooks that shaped Alok's thinkingFinal advice on building with both impact and economic successChapters00:00 Intro to Alok Tayi and the mission behind Vibe Bio01:09 From scientist to serial founder in life sciences software03:16 How Alok's daughter's diagnosis changed his life and career04:28 Leadership lessons from scaling companies at different stages06:48 What Vibe Bio actually does and how its AI works10:37 Why biotech and pharma are harder than most founders expect13:51 Balancing regulation, speed, and commercial reality15:54 Why rare disease communities have been historically overlooked17:38 Why rare disease innovation may become more viable now19:25 Why non-scientists can still play a major role in biotech22:04 Capital efficiency, biotech cycles, and the real funding question24:33 Why AI is an accelerant for biotech, not a replacement26:57 The rise of parent-led and unconventional biotech founders29:50 Vibe Bio's AI platform versus its venture fund33:43 Platform companies vs. individual therapy companies37:12 How AI-driven evaluation changes therapeutic investing39:48 Alok's biggest business and culture lessons as a founder43:15 Books that shaped Alok's thinking46:22 Final advice on building with both impact and economic success48:29 Where to find Alok and Vibe BioAlok Tayi's Social Media Links:https://www.linkedin.com/in/aloktayi/https://x.com/aloktayiResources and Links:⁠⁠⁠⁠⁠https://www.hireclout.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.podcast.hireclout.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/hirefasthireright⁠

In this episode of Data in Biotech, host Ross Katz sits down with Ben Locwin, Vice President at Reliant Life Sciences, to explore the evolving landscape of artificial intelligence in biotechnology.  Join us as we discuss why nearly every biotech claims to use AI but few actually do, examine successful applications like AlphaFold, and explore the challenges of implementing AI across drug development, manufacturing, and regulatory processes. Ben shares insights on maintaining healthy skepticism, understanding data provenance, and looking ahead to what this year may bring for AI in life sciences. What you'll learn in this episode:  >> The AI hype problem in biotech and why most companies claim to use AI but few actually do. >> AlphaFold as the gold standard and how DeepMind's protein structure prediction model represents the most successful application of AI in biotech >> Data quality over algorithmic sophistication and the critical importance of data provenance, examining primary sources, and understanding that data quality matters more than the complexity of the AI model >> The balance between optimism and evidence-based decision-making, distinguishing between sophisticated AI and advanced statistical modeling Meet our guest: Ben Locwin is a healthcare and life sciences executive and medical scientist known for helping bring pharmaceuticals, vaccines, and medical devices to market faster and with higher quality. A TEDx speaker and seasoned leader, he's worked across major biotech hubs and has deep expertise in global regulatory pathways, having collaborated with the FDA, EMA, MHRA, PMDA, and more. Connect with Ben Locwin on LinkedIn  About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

What does it really take to build a sustainable biotech ecosystem outside of traditional hubs like Boston and San Francisco? In this episode, host Elaine Hamm, PhD, is joined by Christin Godale, PhD, Executive Director of LifeSciKY, to explore how regional innovation communities can grow from the ground up. Christin shares how LifeSciKY is helping entrepreneurs access lab space, shared equipment, mentorship, and community support. The conversation dives into the realities of building biotech infrastructure in emerging regions, and why success comes from leaning into local strengths, building partnerships, and creating opportunities for founders to succeed where they are. In this episode, you'll learn: Why successful biotech ecosystems rely on strong partnerships between government, industry, and academia. How regions outside traditional biotech hubs can build sustainable innovation communities by leveraging their unique strengths. What incubators and shared lab spaces must provide beyond real estate to truly support founders and early-stage companies. Tune in to learn how collaborative communities and intentional partnerships can transform regional innovation ecosystems and create new opportunities for biotech entrepreneurship. Links: Connect with Christin Godale, PhD, and learn about LifeSciKY. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine, as well as Cadenza Bio. Learn more about Thermo Fisher Scientific, Project Medtech, and SmartHealth Catalyzer. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Scott Wapner and the Investment Committee are live at Future Proof Citywide in Miami Beach, Florida to debate the turnaround in the markets and how they are trading it. Plus, we hit the latest Calls of the Day. And later, Josh Brown spotlights some Biotech names in his "Best Stocks in the Market." Investment Committee Disclosures Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?John: Ability to believe without evidence.In what world does it make sense to have the most important two parts of the value chain have the least power? That is the question John Tabis asked before launching The Bouqs Company. By recognizing that both flower farmers and consumers were being ignored by the traditional floral industry, he found a unique way to disrupt the market.In today's episode, John shared how his company deploys technology directly at the source. Instead of flowers passing through five or six layers of middlemen, farmers cut, prep and pack the product to send directly to the consumer. This model drastically reduces waste and increases freshness.“We thought, what an amazing opportunity to build a new supply chain that simplifies that supply chain, uses technology to deliver the freshest, high quality, sustainable blooms,” John explained.Since launching with just a few thousand dollars in the bank, the company has generated over a billion dollars in gross revenue. Customers love the value and they deeply resonate with the brand's commitment to sustainability.Now, John is taking community engagement to the next level. The Bouqs Company is currently raising capital through a regulated investment crowdfunding campaign. This allows loyal customers and everyday investors to own a piece of the business.John noted that turning a customer base into an investor base creates a massive crowd of brand promoters. When people invest in a company they love, they naturally share its mission with friends and family.The current regulation crowdfunding campaign is capped at $5 million and is filling up quickly. The funds will be used to expand their physical retail footprint nationwide to offer faster delivery and fully arranged vases.If you want to support a sustainable business model and own a stake in a rapidly growing brand, this is a remarkable opportunity to align your investments with your values.tl;dr:John Tabis revolutionized the floral industry by connecting sustainable farms directly to everyday consumers.The Bouqs Company reduces waste and ensures fresher flowers by eliminating unnecessary supply chain middlemen.The company is currently raising up to $5 million through a regulated investment crowdfunding campaign.John relies on his superpower of unending faith to navigate the toughest entrepreneurial challenges successfully.In today's episode we learned that combining strong convictions with flexibility drives massive business growth.How to Develop Unending Faith As a SuperpowerJohn defines his superpower as having unending faith. He describes it as “the ability to believe without evidence” and notes that as an entrepreneur he consistently has faith in a better future. He believes that “there's a better step ahead” and that “a better version of ourselves, of our companies, of our products [is] around the corner.” This unwavering belief serves as the absolute cornerstone of his journey as a founder.A powerful example of this faith occurred during the company's Series B fundraising round about eight or nine years ago. The business was burning cash and was literally weeks away from running completely out of money. John's VP of finance asked when they should pull the emergency cord to start cutting costs. Relying on his unending faith, John told him not to worry. Just four or five days before their cash ran out, they received a term sheet and successfully closed the capital needed to keep the business thriving.To develop unending faith as a personal strength, John offers the following actionable tips:Maintain very strong convictions but hold them loosely so you can adapt when necessary.Be 100 percent sure of your vision until you receive clear evidence that you need to pivot.Remain highly flexible and willing to shift your strategy dramatically based on market feedback.Iterate your way to the right solution instead of getting trapped by narrow-minded tunnel vision.By following John's example and advice, you can make unending faith a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileJohn Tabis (he/him):Founder & Chairman, The Bouqs CompanyAbout The Bouqs Company: Bouqs is a digital first online disruptor of the $100B global floral market leveraging technology to improve the customer experience with flowers.Website: bouqs.comCompany Facebook Page: facebook.com/thebouqsco Company Twitter Handle: @thebouqsco Other URL: invest.bouqs.comBiographical Information: John Tabis is a visionary, a strategist, a marketer, and a Founder. John is currently Founder & Chairman of the Board at The Bouqs Company, Partner & Head of Incubation at M13, and Professor of Entrepreneurship at UCLA Anderson. Prior to these roles John worked at global management consulting firm Bain & Company, and in Strategy & Innovation at The Walt Disney Company. John studied Business at The University of Notre Dame, where he graduated Summa Cum Laude, and earned his MBA at the UCLA Anderson School of Management, where he studied on Fellowship. Jon resides in Southern California with his wife and three children. LinkedIn Profile: linkedin.com/in/jtabisInstagram Handle: @jtlives4thisSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include rHealth, and Frontier Bio. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Superpowers for Good Live Pitch – Private Investor Session: Immediately following the March 17, 2026, live broadcast at 8 PM ET / 5 PM PT, investors are invited to join an exclusive private Zoom session to engage directly with the presenting founders—BRG Therapeutics (Dale Walker), GigaWatt (Deep Patel), My Diabetes Health (Dr. Prem Sahasranam), and rHEALTH (Eugene Chan). In this dedicated off-air environment, participants can ask deeper questions about strategy, traction, deal terms, and impact while exploring their active Regulation Crowdfunding campaigns in real time. Watch the live pitches on Roku, Amazon Fire TV, LG Smart TVs via e360tv, LinkedIn, YouTube, or Facebook—then continue the conversation in the private investor session where capital and clarity come together. Register free to get access to both events.SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on March 17th at 1:30 PM ET/10:30 AM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!SuperCrowdHour March: This month, Devin Thorpe will explore how investors can align profit with purpose in a powerful session titled “Why You Should Make Money with Impact Crowdfunding.” As CEO and Founder of The Super Crowd, Inc., Devin will share practical insights on generating financial returns while driving measurable social and environmental impact through regulated investment crowdfunding. Register free to get all the details. March 18th at Noon ET/9:00 PT.SuperCrowd26 featuring PurposeBuilt100™: This August 25–27, founders, investors, and ecosystem leaders will gather for a three-day, broadcast-quality global experience focused on disciplined capital formation, regulated investment crowdfunding, and purpose-driven growth. We're bringing together leading voices in impact investing, compliance, digital marketing, and circular economy innovation to deliver practical frameworks, real-world case studies, and actionable strategies. The event culminates in the PurposeBuilt100™ Showcase, recognizing 100 of the fastest-growing purpose-driven companies in the U.S. Register now to secure your seat and get all the details. August 25–27, streaming worldwide.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Nominate your MedTech, BioTech or Life Sciences company for the prestigious TAG Awards. The deadline is quickly approaching! Apply before March 13! Use the discount code SUPERPOWER to save 20%!If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Gina Ford, CEO, BioNTX

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion's partnership strategy, and operating a biotech in the Houston, Texas clinical hub. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM 2026 in San Francisco, host Alok Tayi speaks with Cary Claiborne, CEO of Adial Pharmaceuticals, about a new precision-medicine approach to tackling one of the world's most widespread and undertreated conditions: alcohol use disorder. Cary shares the personal and professional journey that brought him into addiction medicine—from a career in finance at global corporations to helping take pioneering biotech companies public and ultimately leading Adial's mission to address addiction through science. After losing a close family member to addiction, Cary became determined to focus his work on diseases where innovation could create meaningful societal impact. The discussion explores Adial's genetically targeted therapy, designed to reduce alcohol cravings without requiring patients to stop drinking entirely. Cary explains how their repurposed low-dose therapy, paired with a simple cheek-swab diagnostic test, could help identify the patients most likely to benefit—bringing a precision-medicine framework to addiction treatment, an area that has seen little therapeutic innovation in more than two decades. Alok and Cary also examine the broader landscape of addiction science, the societal costs of untreated alcohol use disorder, and how AI-driven clinical simulations are helping design smarter Phase III trials. Looking ahead, Cary discusses how this scientific platform could expand into other impulse-driven conditions, including opioid addiction, gambling, and compulsive behaviors. It's a compelling conversation about precision psychiatry, addiction medicine, and the future of neuropsychiatric drug development. Biography: Cary Claiborne was named Chief Executive Officer of Adial Pharmaceuticals in August 2022 after previously being appointed Chief Operating Officer in December 2021 and being named to the Board of Directors. Mr. Claiborne previously served as Chief Financial Officer (CFO) and board member of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. Among his accomplishments, Mr. Claiborne led the company's spin off from its then parent company, Reckitt Benckiser, to become an independent, listed company. While at Indivior, he established and oversaw corporate reporting, internal audit, tax, treasury, external audit, and information technology. Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt. Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc., and oversaw corporate finance during the company's initial public offering. He graduated from Rutgers University with a B.A. in Business Administration and from Villanova University with an M.B.A. and was a National Association of Corporate Directors (NACD) Governance Fellow.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

  Aging in Place: Safety, Technology, & Dignity w/ Drew Siefried of TruBlue Ally - AZ TRT S07 EP04 (286) 3-1-2026       Things We Learned This Week ·         America is aging rapidly - By 2030, 1 in 5 Americans will be over 65. ·         Most seniors want to stay in their homes - More than 80% of older adults prefer aging in place rather than moving to assisted living. ·         Technology is transforming senior safety - Non-intrusive monitoring systems can detect falls and alert families without cameras or wearables. ·         One fall can change everything - Falls are one of the leading causes of injury and loss of independence among seniors. ·         Prevention is far cheaper than crisis care - Simple home safety upgrades can prevent accidents and help seniors maintain independence longer.     Guest: Drew Seifried LKIN: https://www.linkedin.com/in/drewseifried/ Company: TruBlue Home Service Ally Website: https://www.trublueally.com/east-phoenix-north-scottsdale   With over 25 years of combined corporate and entrepreneurial experience, I currently own and operate TruBlue Home Service Ally, where we support seniors and busy families with home modifications and handyman services. In this role, we prioritize safety, reliability, and exceptional service, ensuring all personnel meet high professional standards. As a Certified Franchise Executive, I also guide aspiring entrepreneurs, including corporate professionals, first responders, and military veterans, toward business ownership through franchising. Leveraging expertise in franchise agreements and processes, I simplify the path to ownership, aligning opportunities with individual goals. My mission is to empower others to achieve their aspirations through purpose-driven ventures.   TruBlue Home Service Ally® provides a unique and affordable approach to helping busy adults and seniors live a worry-free life by offering trustworthy handyman, home maintenance and senior modification services. Helping you maintain your home both inside and out, TruBlue's services include: handyman projects and to-do list chores, preventative home maintenance programs, seasonal work, and senior modification services, all handled by a professional, bonded and insured Tru-Pro® Technician. Episode Overview America is entering a major demographic shift. By 2030, 1 in 5 Americans will be over the age of 65, creating what many experts call the "Silver Tsunami." Families across the country will face new challenges as aging parents want to maintain independence while staying safe at home. But aging at home safely requires planning. In this episode, we sit down with Drew Seifried of TruBlue Home Service Ally to discuss how home safety modifications, emerging Age Tech, and non-intrusive monitoring technologies are helping seniors stay independent longer — while providing peace of mind for their families. We also explore the unique needs of veterans and individuals with disabilities, and how communities and organizations can better support them.   Segment 1: Aging in Place & The Silver Tsunami Drew Seifried owns three territories with TruBlue, a national franchise focused on helping people safely remain in their homes. The company works primarily with: ·         Seniors and aging adults ·         People with disabilities ·         Veterans ·         Adult children caring for aging parents Their mission is simple: help people live independently and safely at home. The Growing Senior Population America is rapidly aging. Key statistics: ·         61 million Americans are age 65+ ·         By 2030, about 20% of the population will be seniors ·         Phoenix and other Sun Belt cities are seeing rapid senior population growth as retirees relocate This demographic shift will place new pressure on: ·         Healthcare systems ·         Caregiver workforce ·         Family members caring for aging parents The Hidden Risk: Falls in the Home One of the biggest threats to senior independence is falling. Key statistics: ·         1 in 4 adults age 65+ falls each year ·         Falls cause over 3 million emergency room visits annually ·         More than 300,000 seniors are hospitalized each year for hip fractures ·         Over 50% of falls occur inside the home In many cases, one fall can change everything. A serious fall can lead to: ·         Hospitalization ·         Loss of mobility ·         Long-term disability ·         Moving into assisted living The Most Dangerous Areas in a Home According to home safety experts, the highest risk areas include: ·         Bathrooms (tubs and showers) ·         Entryways and stairs ·         Poor lighting ·         Cluttered hallways or walkways Even small modifications can dramatically reduce fall risk. Preventing Falls Before They Happen TruBlue helps families install preventative safety upgrades such as: ·         Bathroom grab bars ·         Non-slip shower treatments ·         Improved lighting ·         Handrails and stair supports ·         Walkway hazard removal The company also performs full home safety assessments to identify hidden risks. As Drew explains, the goal is prevention — because once a fall happens, recovery can be much more difficult. Aging at Home vs Assisted Living Another major challenge families face is cost. Average assisted living costs in the U.S.: ·         $5,000–$6,000 per month ·         Often $60,000–$70,000 per year By comparison, many safety upgrades or in-home services cost a fraction of that. And most seniors prefer to stay home. Surveys show: ·         84% of seniors want to age in place ·         Independence and familiarity with their home environment matter deeply Segment 2: Age Tech & Smart Monitoring One challenge facing families is the shrinking caregiver workforce. With fewer caregivers available, technology is stepping in to help monitor safety. Adult children want peace of mind that their parents are safe — especially when they live in another city. But many seniors dislike traditional monitoring systems. Common concerns include: ·         Cameras in the home ·         Wearable emergency devices ·         Privacy issues ·         Technology complexity A New Approach: Radar-Based Monitoring A newer technology solution is radar-based monitoring systems like those from Pontosense. These systems use small radar sensors placed throughout the home. They can detect: ·         Falls ·         Movement patterns ·         Breathing and vital signals Unlike cameras, they are completely non-intrusive. Features include: ·         No cameras ·         No wearable devices ·         No audio recording ·         No stored video data The system can detect unusual events and send alerts. Smart Alerts for Families If a fall occurs, the system can: ·         Wait about 90 seconds to see if someone gets up (reducing false alerts) ·         Send notifications to family members ·         Contact caregivers ·         Alert emergency services if necessary Family members can also monitor activity patterns through a mobile app. For adult children balancing careers, families, and aging parents, this technology provides peace of mind without invading privacy. Segment 3: Disability Services & Veteran Support TruBlue also works with individuals living with disabilities and veterans who require specialized home modifications. Organizations supporting the disability community include: ·         Ability360 ·         Benevilla These groups offer programs ranging from adaptive sports to community support services. Health Challenges as We Age Many older adults face conditions that impact mobility or independence. These can include: ·         Arthritis ·         Balance issues ·         Progressive neurological diseases like ALS or MS ·         Reduced strength and coordination Simple tasks — getting into a bathtub, climbing stairs, or reaching shelves — can become difficult. Home modifications can restore independence. Importantly, these upgrades can be designed to blend into the home aesthetically, preserving both function and dignity. Supporting Veterans Veterans represent another group that often needs home safety support. Key statistics: ·         Approximately 17 million veterans live in the United States ·         Nearly 8 million veterans are age 65 or older Despite available programs, many veterans do not utilize assistance. Organizations working to support veterans include: ·         Paralyzed Veterans of America ·         Veterans of Foreign Wars ·         Elks Lodge Drew himself served in the military and is passionate about helping veterans access services and resources. Additional Home Safety Monitoring Beyond fall prevention, modern smart homes can also monitor: ·         Smoke and fire detection ·         Water leaks and flooding ·         Utility failures ·         Entry and exit activity These systems help families create a safer living environment for aging loved ones.   Final Takeaway Aging doesn't have to mean losing independence. With the right combination of: ·         Home safety modifications ·         Smart technology ·         Community resources ·         Family planning Millions of seniors can live longer, safer, and more confidently in their own homes.       'Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ 'Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.    

When scientists began tinkering with DNA in the 1970s, biotechnology was not welcome in leafy residential neighborhoods or many college towns. But it was embraced by an industrial city by the Bay. In today's episode we come to learn how South San Francisco became one of the world's most valuable hubs of biotech. Additional Resources: How South San Francisco Became the Birthplace of Biotechnology Read the transcript for this episode Sign up for our newsletter Got a question you want answered? Ask! Your support makes KQED podcasts possible. You can show your love by going to https://kqed.org/donate/podcasts This story was reported by Lesley McClurg. Bay Curious is made by Katrina Schwartz, Christopher Beale and Olivia Allen-Price. Additional support from Jen Chien, Katie Sprenger, Maha Sanad, Ethan Toven-Lindsey and everyone on Team KQED. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

John is joined by Jonathan Graham, Executive Vice President and General Counsel and Secretary of Amgen, one of the world's largest biotech companies and one of the pioneers of the industry. They discuss in-house legal leadership in major biotech companies and how science, intellectual property, and regulation shape strategy. Jonathan began his practice clerking for the Ninth Circuit Court of Appeals, then became a litigator for a large firm. Later, his career shifted in-house. He believes that litigation training develops useful skills, including rapid issue spotting across unfamiliar domains, crisp written and oral advocacy, and an ability to understand stakeholders' incentives.The biotech industry is unusually purpose-driven because the output is medicine that can extend life and restore quality of life. That mission creates urgency across functions, as delays can mean patients wait longer for needed therapies. The sector is also highly regulated and fast-moving, which elevates the importance of legal teams that operate as strategic partners rather than as a “department of no.”Intellectual property is the economic lifeblood of biological drug development. Bringing a molecule to market often costs billions of dollars and requires years of lab work, clinical trials, and manufacturing scale-up. Without enforceable patents, competitors could free ride, undermining investment incentives. This reality drives frequent, high-stakes patent disputes that can be hard to settle because exclusivity is enormously valuable.Patent doctrines often lag behind technology, forcing courts to fit new technologies into older legal frameworks. Artificial intelligence is potentially a powerful tool for discovery and analysis of molecules, but not a substitute for wet-lab validation or human inventorship. Regulators still require clinical evidence before any medicine is approved and likely will for the foreseeable future.Biosimilars are currently a booming market with many parallels to generic drugs. A company may participate in the market as both innovator and biosimilar supplier by leveraging its research and manufacturing capabilities. Finally, government-driven drug pricing controls may slow innovation over time, even though scientific progress and therapeutic potential remain strong.Podcast Link: Law-disrupted.fmHost: John B. Quinn Producer: Alexis HydeMusic and Editing by: Alexander Rossi

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a powerful conversation at the intersection of biotech innovation, leadership, and personal transformation. Sheila shares the unconventional journey that led her from academic medicine to the forefront of biotechnology—spanning roles at Genentech and Bristol Myers Squibb, founding companies, serving on boards, and recently helping guide Ventus Therapeutics through its acquisition by Lilly. Along the way, she reflects on the lessons she learned building drugs, scaling companies, and navigating the evolving biotech deal environment. The discussion then turns deeply personal as Sheila explores the ideas behind her book “The Mirror Effect,” revealing how self-awareness, supportive networks, and authentic leadership can transform careers—especially for women and underrepresented leaders in science. From overcoming imposter syndrome to building the “CEO Sisterhood” network of women biotech leaders, Sheila shares hard-earned insights on navigating power, culture, and identity in high-stakes industries. For founders, investors, and leaders alike, this episode blends biotech strategy with deeply human lessons on resilience, purpose, and the power of believing in yourself. Biography: SHEILA GUJRATHI, MD, is a biotech entrepreneur, executive, and champion for under- represented leaders. Over the past 25 years, she's had the privilege of developing life-changing medicines for patients with serious diseases while building and running private and public biotech companies—including some exciting exits. Today she's a founder, chairwoman, board director, strategic advisor, and consultant to start-up companies and investment funds. Dr. Gujrathi was the co-founder and former CEO of Gossamer Bio and former Chief Medical Officer of Receptos. Her journey started at Northwestern University, where she earned both her M.D. and biomedical engineering degree, and took her from the halls of Harvard, UCSF, and Stanford to the corporate offices of Fortune 500 companies like McKinsey, Genentech, and Bristol-Myers Squibb. Dr. Gujrathi has earned multiple leadership awards, including AIMBE Fellow, BLOC100 Luminary, Healthcare Technology Report Top 25 Women Leaders in Biotechnology, Corporate Directors Forum Director of the Year, and Fiercest Women in Life Sciences. But what really lights her up is creating the inclusive environments she wished she'd had throughout her career. That's why she co-founded the Biotech CEO Sisterhood, a group of trailblazing female CEOs—because we're all better when we support each other.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that highlight the intricate interplay of scientific innovation, regulatory dynamics, and strategic maneuvers shaping the industry.Starting with Moderna, the company has reached a pivotal resolution in a long-standing patent dispute involving its mRNA-based COVID-19 vaccine, Spikevax. This settlement involves a hefty $950 million payout to Genevant Sciences and Arbutus Biopharma, resolving claims of patent infringements. This agreement underscores the complex nature of intellectual property in the rapidly evolving mRNA landscape. Securing patent rights is crucial as new vaccines and therapies are developed, and this resolution not only clears a legal hurdle for Moderna but also exemplifies the industry trend towards resolving such disputes to foster continuous innovation.Sanofi has embarked on a significant strategic move by entering a $1.53 billion global licensing deal with Sino Biopharmaceutical. This agreement secures rights to a first-in-class JAK/ROCK inhibitor, which shows promise in treating hematological and immunological conditions. Such collaborations reflect the increasing focus on innovative therapies that target complex biological pathways, highlighting how companies are seeking unique assets to bolster their competitive edge.Regulatory scrutiny continues to be a formidable theme in the industry. The FDA has intensified its oversight on compounded GLP-1 drugs, issuing 30 warning letters to telehealth companies marketing unauthorized versions. This action highlights the agency's commitment to ensuring drug safety and efficacy while emphasizing the challenges companies face in navigating regulatory landscapes for compounded medications. Additionally, Novo Nordisk has been cautioned by the FDA regarding advertising practices for GLP-1 receptor agonists, illustrating the ongoing regulatory focus on pharmaceutical marketing strategies and compliance standards.Meanwhile, Bayer is experiencing a period of resilience in its pharmaceutical division, driven largely by its cancer drug Nubeqa and cardiovascular agent Kerendia. Despite these successes, Bayer faces challenges as revenues from older drugs like Xarelto and Eylea decline. This scenario reflects a broader industry challenge where companies must innovate while managing mature product lines facing generic competition.Teva Pharmaceuticals is making strategic strides by securing a $400 million deal with Blackstone to develop an anti-TL1A antibody for inflammatory bowel disease (IBD), in partnership with Sanofi. This investment highlights continued interest in autoimmune and inflammatory conditions as lucrative targets for novel therapies. Financial partnerships like Teva's substantial agreement with Blackstone illustrate how such collaborations can support sustained R&D efforts in chronic disease management.Technological integration into healthcare is expanding rapidly, with Nvidia collaborating with Droplet Biosciences to explore AI applications in medtech and cancer research. These partnerships illustrate an industry shift towards leveraging artificial intelligence to enhance diagnostic capabilities and accelerate research efforts. Moreover, collaborations leveraging AI/ML technologies across drug discovery pipelines are gaining traction; Earendil Labs partnering with WuXi XDC exemplifies this trend alongside Merck & Co.'s multi-year AI oncology data deal with Tempus—enhancing precision medicine capabilities while expediting therapeutic discoveries.In terms of funding new therapeutic areas, ARPA-H has announced a $158 million initiative aimed at developing medicines targeting the lymphatic system. This marks an exploration into less charted territories within physiological research that could yield transforSupport the show

In this Denatured episode, Jennifer C. Smith-Parker speaks to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We'll discuss how best to tailor an investment approach of both nondilutive funding and family offices to overcome the drug development valley of death. Host⁠Jennifer Smith-Parker⁠, Director of Insights, BioSpaceGuestsRam May-Ron, Managing Partner, FreeMind GroupRavi Kiron, Managing Director, Biopharma Strategy AdvisorsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

This is for the woman who's aiming for a promotion (or a bigger external role) and keeps thinking, If I could just get that title, everything would feel different.Today we are going beyond the title to talk about the messy middle, what drives advancement and the critical part needed to reach your advancement goal. When you don't understand your deeper “why,” you can end up pushing for something that isn't actually the solution… or finally getting it and realizing it feels hollow.In this episode, you'll learn:Why I ask “why” first when someone says they want a promotion title—and the common answers that quietly stall progressThe three deeper drivers I hear most often and what each one actually requires in Pharma/BiotechWhy “I earned it” and “I work hard” rarely works as a promotion strategy in complex organizationsGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here. Work with Me: Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Math doesn't have to be intimidating, especially when it's the kind that helps fund companies and move science forward. In this episode, host Elaine Hamm, PhD, is joined by Isaiah Reeves, PhD, Biomedical Analyst at Solas BioVentures, for a practical and approachable deep dive into venture math. Drawing on his background as a scientist turned investor, Isaiah breaks down the core financial concepts every biotech founder should understand: from valuations and dilution to IRR, cap tables, and deal terms. The conversation offers real-world guidance for navigating fundraising, choosing the right partners, and avoiding common pitfalls that can derail long-term value creation. In this episode, you'll learn: How venture capitalists think about valuations, dilution, and returns, and why fully diluted post-money matters. Key metrics like IRR and DPI, and how they influence investment decisions and fund performance. Common deal terms and cap table “red flags” founders should watch out for as they raise capital. Tune in to learn how understanding venture math can help founders make smarter funding decisions, protect long-term value, and build biotech companies positioned for sustainable growth and impact. Links: Connect with Isaiah Reeves, PhD, and check out Solas BioVentures. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine, as well as Cadenza Bio. Connect with Josh Eckelberry, MBA, and Mark Corrigan, MD. Check out the books The Go-Giver and Venture Deals. Check out the podcasts STAT, Biotech Hangout, and 20VC. Check out our previous episodes on Networking as an Introvert and Solas BioVentures with Travis Manasco. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

From academic deep‑tech to the front lines of Biotech entrepreneurship - Eline Koers' journey is a masterclass in courage, clarity, and reinvention. After years immersed in structural biology and membrane protein folding, Eline realised she wanted her work to have real‑world impact. That shift pulled her out of academia, into translational science, and eventually into founding AAB Therapeutics - a company engineering extracellular vesicles to solve one of oncology's biggest challenges: getting drugs where they need to go. In this conversation, Eline shares the turning points that shaped her path, discussing the importance of curiosity, timing, and daring to step into the unknown - even when the success rate is small and the learning curve is steep. A brilliant episode for anyone considering a move from academia into Biotech, or thinking about building something of their own.

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Patients who need kidney dialysis live all over the world - even in some of the remotest regions. They need updated equipment, trained healthcare staff, and lots of clean water. Chris Atwater, Director of Technical Operations at the nonprofit Bridge of Life, helps bring hope to these areas. He has traveled to six continents for his life's work, using skills he learned as a United States Marine and the education he acquired for this role. If you are interested in learning more about challenges facing dialysis patients in remote areas, check out this video we made about services in the Australian bush. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and ongoing challenges that are reshaping the landscape of these dynamic industries.A key highlight in recent developments comes from Ascendis Pharma, which has secured FDA approval for Yuviwel, a treatment targeting achondroplasia, a genetic disorder leading to dwarfism. This approval underscores the potential of Ascendis' "transient conjugation" drug delivery platform, marking its third rare disease drug approval in just six years. The platform's ability to extend drug half-life and improve dosing frequency highlights its promise in addressing unmet medical needs in rare diseases, offering new hope for patients who previously had limited treatment options.In oncology, Merck's LITESPARC clinical trial program is showing promising results with Welireg (belzutifan) for clear cell renal cell carcinoma. The trials suggest that combination therapies involving Welireg could set a new standard of care. However, transitioning these regimens into universal standards remains challenging due to competitive dynamics and hurdles in clinical adoption.Shifting to cardiovascular health, United Therapeutics has made notable progress with its phase 3 trial success for a once-daily drug candidate for pulmonary arterial hypertension. The trial reported a 55% reduction in clinical worsening risk, positioning United Therapeutics to seek FDA approval and potentially challenge existing treatments from major players like Johnson & Johnson.Regulatory challenges are also evident. UniQure recently faced a setback when the FDA rejected its data package for AMT-130, a gene therapy for Huntington's disease. This rejection reflects the stringent regulatory environment surrounding gene therapies and emphasizes the need for robust data to meet approval criteria.On the technological front, Eli Lilly is making a strategic shift by collaborating with Nvidia to integrate advanced computing capabilities into drug development. By leveraging Nvidia's AI-driven supercomputing power, Lilly aims to accelerate drug discovery processes and enhance precision medicine approaches, potentially transforming traditional pharmaceutical lifecycles.Operational shifts are also occurring as Merck winds down Gardasil production at its North Carolina plant due to declining global demand. This decision reflects broader vaccination trends and may signal shifts in manufacturing strategies to align more closely with market demands.Leadership changes at Bavarian Nordic, following a failed private equity takeover bid, indicate potential strategic realignments within the company. The planned departure of CEO Paul Chaplin after 12 years could herald new directions and priorities.In logistics, Frontier Scientific Solutions is pioneering advancements in temperature-controlled supply chains—crucial for maintaining drug efficacy during distribution. Their innovative approaches are reshaping pharmaceutical logistics, ensuring reliable delivery systems worldwide.Meanwhile, Walgreens is venturing into digital health with a virtual weight management clinic offering access to GLP-1 medications. This move positions Walgreens within the competitive telehealth market as it responds to growing consumer demand for convenient healthcare solutions.These developments collectively reflect an industry in flux—balancing scientific innovation with regulatory rigor and strategic realignments. As companies navigate these challenges, the implications for patient care are profound, promising potential improvements in treatment efficacy and accessibility.Turning our attention to Roche, another successful Phase 3 trial for fenebrutinib—a BTK inhibitor targeting relapsing multiple sclerosis—has been reported. The study achieved its primary endpoint but raiseSupport the show

Doug Crawford, Ph.D., is the founder of MBC BioLabs and also a Managing General Partner of Mission BioCapital. Doug's goal is to help entrepreneurial scientists create successful startups. His dream is that every entrepreneurial scientist with a dream be given a chance.  Since its founding, this program has helped launch 500 companies and helped raise over $20 billion in capital. Robert Blazej, Ph.D., is a Partner at Mission BioCapital and Director at MBC BioLabs. He is a passionate biotechnologist with a diverse skillset spanning business, life science, engineering and intellectual property. Robert Blazej brings 10 years of operational experience both as a successful entrepreneur and as a leader within an international corporation. Previously, Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that microdroplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013. This conversation can be considered as the 2026 State of the Union for early-stage biotech. The biotech landscape has shifted drastically- we moved from the grow-at-all-costs zero-interest-rate era to a world of tight capital and high discipline. The undisputed capital of biotech in Boston is facing unprecedented lab vacancies. AI is dominating every pitch deck. And China has rapidly evolved from a manufacturing hub into a multi-billion-dollar discovery engine.   Shownotes https://mbcbiolabs.com/; https://www.missionbaycapital.com/ How did Doug and Robert meet? Progress Mission Biolabs made in the past 4 years God's eye view of the biotech startup world- What is being built? DNA of the founders: repeat founders on the rise Capital restraints and advances in science made the current period the best time to launch biotech startups. With the advent of AI, we should not be making knowable mistakes Companies are using AI to jumpstart what they are going to work on Discovery costs are the overall cost of drug discovery- So, don't get too excited! How to address reduction in NIH non-dilutive funding ⅓ of startups in incubators are serial entrepreneurs; ⅓ are mid-career scientists from established companies  Comparing Boston and the Bay area biotech ecosystems 73% of pharma's revenues are from discoveries sourced externally Alternate models: Arena bioworks, Arc Institute, Chan Zuckerberg institute Book recommendation - Thinking in Bets Actual impact of AI at Mission Biolabs Where Ai might have the most impact- healthcare delivery? China affairs: Regulatory changes, investments, return of talent European biotech affairs

Navigating Talent Optimization: Strategic Staffing and Leadership with Robert HowardIn this episode of The Thoughtful Entrepreneur Podcast, host Josh Elledge speaks with Robert Howard, Director of Recruiting Operations and Executive Leadership Coach at Magic Talent Solutions, about the evolving complexities of the modern workforce. As a military veteran and seasoned business owner, Robert brings a unique perspective to the high-stakes world of recruitment, offering deep dives into bridging staffing gaps and upskilling internal teams. This conversation serves as a strategic guide for founders and executives who are navigating the post-pandemic market correction and seeking to balance the efficiency of AI with the irreplaceable value of human judgment in leadership.Optimizing the Human Element in Modern RecruitmentThe current recruiting landscape requires a sophisticated blend of agility and specialized expertise to overcome the "ebb and flow" of market demands. Robert observes that while many organizations surged with over-hiring in previous years, 2026 is defined by stabilization and a more project-based approach to talent acquisition. For companies struggling with mission-critical, hard-to-fill roles, the solution often lies in moving beyond basic job postings toward advanced sourcing strategies that identify passive talent. By aligning staffing levels with specific project needs and maintaining a flexible workforce of both full-time and contract professionals, businesses can protect their bottom line while ensuring they have the right hands on deck for every initiative.Transitioning from an individual contributor to a leadership role remains one of the most common stumbling blocks for growing enterprises. Robert emphasizes that effective leadership development is not a "one-size-fits-all" endeavor; it requires tailored coaching that draws on proven principles of communication and accountability. Many companies find their internal recruiting teams are comprised of junior staff who lack the nuance required for high-level interviewing or the deep understanding of complex employment laws, such as those specific to California. Upskilling these internal teams through hands-on training ensures that the first point of contact for new talent is professional, compliant, and capable of identifying the subtle cultural fits that drive long-term retention.The integration of AI in recruitment offers significant efficiency gains, but it also introduces new risks regarding bias and candidate experience. While AI excels at administrative heavy lifting—such as interview scheduling and bulk follow-ups—Robert cautions that it is not yet a reliable substitute for human intuition in the final selection process. Relying solely on algorithms for candidate screening can lead to unintentional bias and even legal complications. Successful organizations use AI as a tool to free up their human recruiters for high-value relationship building, ensuring that the final "yes" is always determined by a person who can sense the intangible qualities that make a candidate truly exceptional for a specific team.About Robert HowardRobert Howard is the Director of Recruiting Operations at Magic Talent Solutions and a dedicated Executive Leadership Coach. With a background rooted in military service and entrepreneurial leadership, he specializes in identifying talent patterns and helping organizations build high-performing teams. Robert is passionate about professional development, often using his experience as an escape room enthusiast to teach the principles of collaborative problem-solving and strengths-based task management.About Magic Talent SolutionsMagic Talent Solutions is a premier staffing and consultancy firm founded to help businesses navigate the shifting talent landscape. The company provides a holistic approach to people operations, offering specialized recruiting for Biotech, Marketing, and Commercial Sales, alongside internal team training and executive leadership coaching. Magic Talent Solutions focuses on bridging the gap between current organizational capabilities and the high-level talent required to achieve strategic goals.Links Mentioned in This EpisodeMagic Talent Solutions Official WebsiteRobert Howard on LinkedInKey Episode HighlightsThe Metaphor of the Escape Room: Why pattern recognition and playing to individual strengths are the secrets to solving both literal puzzles and business bottlenecks.Recruitment Upskilling: The necessity of training internal hiring teams to handle complex employment regulations and sophisticated candidate sourcing.The 2026 Market Correction: Navigating the shift from over-hiring to stabilized, project-based staffing strategies.AI vs. Human Judgment: Why administrative automation is a win, but candidate selection still requires a human touch to avoid bias.Leadership Transitions: Strategies for helping top-tier individual contributors successfully move into management and executive roles.The conversation with Robert Howard illuminates the path for businesses that want to move away from reactive hiring and toward proactive talent optimization. By investing in the training of internal teams and maintaining a human-centric approach to leadership, organizations can build a resilient culture that attracts and retains the best in their industry.More from The Thoughtful Entrepreneur

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas shares his experiences working in the lab with Dr. Robert Langer, Ph.D., starting up Vivtex around his co-invention (a "GI tract on a chip"), building trust externally and securing the right partnerships, and using a strategic stealth period to refine Vivtex's platform technology before scaling it out. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Physiology connects genes and molecules to whole-body function, shaping every stage of drug discovery and development. In this sponsored episode of The Top Line, Sue Bodine, president-elect of the American Physiological Society and a professor at the Oklahoma Medical Research Foundation, explains why physiology remains central to biomedical innovation. Bodine details how physiology strengthens biotech and pharmaceutical research by clarifying how therapies behave in complex biological systems, identifying unintended effects and supporting stronger regulatory narratives. She also examines the expanding role of physiology in wearable technology, remote patient monitoring and artificial intelligence, where biological context is essential to turning large data sets into clinically meaningful insights. The episode also highlights the society’s campaign, “Physiology: The Science Life Depends On,” aimed at elevating awareness of foundational science amid funding uncertainty. For executives, investors and health care leaders seeking sustainable innovation and patient impact, this discussion underscores a clear message: Breakthroughs depend on physiology. Listen to the full interview.See omnystudio.com/listener for privacy information.

In this episode, Karishma interviews Tim, a patent litigator at Mintz, discussing his journey from a potential medical career to law, the skills gained in law school, and the intersection of biotechnology and law. Tim shares insights on his current role, the importance of scientific knowledge in patent law, and the challenges of explaining complex scientific concepts in legal contexts. He also offers advice for aspiring lawyers and reflects on the future of biotech and patent law in the LA ecosystem. Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

This Biotech CEO Is Helping Prevent Surgical Infections – Meet Dikla Czaczkes Akselbrad, CEO PolyPid $PYPDGuestDikla Czaczkes Akselbrad, CEO PolyPidCompany PolyPidhttps://www.polypid.com/Ticker: $PYPDDikla's BioMs. Dikla Czaczkes Akselbrad serves as the Chief Executive Officer of PolyPid after serving as the company's EVP and CFO since 2017, leading the company's initial public offering on the Nasdaq Global Market in June 2020. Dikla brings more than 20 years of experience leading life sciences companies through critical international strategic, financial and business transitions, including raising over $350 million in various forms in her prior executive roles. Before joining PolyPid in 2014, Dikla served as CFO of Compugen Ltd. (NASDAQ & TASE: CGEN) after serving as CFO of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She received a B.A. in accounting and economics and an MBA from Tel-Aviv University, and is a certified public accountant in Israel.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world's first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Mayer is Director of Engineering Innovation at Aprecia Pharmaceuticals. With a decade of experience across automation, additive manufacturing, and life sciences, he leads the advancement of 3D printing technologies and integrated pharma systems. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guests: Sponsor: CorrDyn, a data consultancyConnect with Jacob Mayer on LinkedIn Connect with Kyle Smith on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Guest: Martin Brenner, Ph.D., Chief Executive Officer and Chief Scientific Officer at iBioCompany: iBio, Inc. (NASDAQ:IBIO)Website: https://ibioinc.com/Martin's Bio:Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Company Description: iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Politics can feel overwhelming - but how can scientists, founders, and biotech leaders effectively engage with policymakers to protect innovation and improve patient outcomes? In this episode, host Elaine Hamm, PhD, is joined by Srinu Sonti, JD, Principal at Lewis-Burke Associates LLC, for a candid and insightful conversation on science, policy, and advocacy. Drawing on his experience on Capitol Hill, in health policy, and working with academic medical centers and startups, Srinu breaks down how innovation, funding, and regulation intersect - and why it's critical for scientists and biotech leaders to have a voice in the policy process. In this episode, you'll learn: Why policymakers want to hear directly from scientists, founders, and innovators, and how those conversations shape decisions. Practical ways universities, startups, and small teams can engage lawmakers beyond sending emails or reacting to crises. How policy choices around clinical trials, AI, global collaboration, and advanced therapies impact patients and the future of biotech. Tune in to learn how building authentic relationships with policymakers can demystify science, strengthen innovation ecosystems, and help move life-saving technologies from the lab to the people who need them most. Links: Connect with Srinu Sonti, JD, and check out Lewis-Burke Associates LLC. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out Pew Charitable Trusts. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My book, Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech is officially out today, and in this special bonus episode, my marketing assistant turns the tables and interviews me about why I wrote this book, how the method came to be, and what I want the reader to feel by the end of it.This isn't a traditional teaching episode. It's more a behind-the-scenes conversation. We talk about the roadblocks I hit in my own 9-to-5, the moment I was told my extra degree and stretch work didn't “count,” and how that experience led me to develop the hidden doors framework.This is honest, unscripted, and be sure to listen to the end to catch the blooper reel.In this episode, you'll learn:The reason I wrote this book — and why I wanted it accessible to every woman in scienceThe story behind “hidden doors” and how roles get created outside the org chartThe career advice I followed early on that slowed me downWhat surprised me most while writing — including what I chose to leave outWhat I hope you feel when you finish the last chapterGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here. Work with Me: Learn more and apply to work with me here. Love the podcast? Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Plus: Renault to take full control of Flexis electric-van. And Nvidia chips for laptop computers set to hit the market this year. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of the Crazy Wisdom Podcast, host Stewart Alsop sits down with Jake Hamilton, founder of Groundwire and Nockbox, to explore zero-knowledge proofs, Bitcoin identity systems, and the intersection of privacy-preserving cryptography with AI and blockchain technology. They discuss how ZK proofs could offer an alternative to invasive identity verification systems being rolled out by governments worldwide, the potential for continual learning AI models to shift the balance between centralized and open-source development, and why building secure, auditable computing infrastructure on platforms like Urbit matters more than ever as we face an explosion of AI agents and automated systems. Jake also explains Nockchain's approach to creating a global repository of cryptographically verified facts that can power trustless programmable systems, and how these technologies might converge to solve problems around supply chain security, personal data sovereignty, and resistance to censorship.Timestamps00:00 Introduction to Groundwire and Knockbox02:48 Understanding Zero-Knowledge Proofs06:04 Government Adoption of ZK Proofs08:55 The Future of Identity Verification11:52 AI and ZK Proofs: A New Era14:54 The Role of Urbit in Technology18:03 The Impact of COVID on Trust20:51 The Evolution of AI and Data Privacy23:47 The Future of AI Models26:54 The Need for Local AI Solutions29:51 Interoperability of Knockchain and BitcoinKey Insights1. Zero-Knowledge Proofs Enable Privacy-Preserving Verification: Jake explains that ZK proofs allow you to prove computational outcomes without revealing the underlying data. For example, you could prove you're over 18 without exposing your full identity or driver's license information. The proof demonstrates that a specific program ran through certain steps and reached a particular conclusion, and validating this proof is fast and compact. This technology has profound implications for age verification, identity systems, and protecting privacy while maintaining necessary compliance, potentially offering a middle path between surveillance states and complete anonymity.2. Government Adoption of Privacy Technology Remains Uncertain: There are three competing motivations driving government identity verification systems: genuine surveillance desires, bureaucratic efficiency seeking, and legitimate child protection concerns. Jake believes these groups can be separated, with some officials potentially supporting ZK-based solutions if positioned correctly. He notes the EU is exploring ZK identity verification, and UK officials have shown interest. The key is framing privacy-preserving technology as protection against "the swamp" rather than just abstract privacy benefits, which could resonate with certain political constituencies.3. The COVID Era Destroyed Institutional Trust at Unprecedented Scale: The conversation identifies COVID as potentially the largest institutional trust-burning event in human history, with numerous institutions simultaneously losing credibility with large portions of the population. This represents a dramatic shift from the boomer generation's default trust in authority figures and mainstream media. This collapse is compounded by the incoming AI revolution, creating a perfect storm where established bureaucracies cannot adapt quickly enough to manage rapidly evolving technology, leaving society in fundamentally unmanageable territory.4. Centralized AI Models Create Dangerous Dependencies: Both speakers acknowledge growing dependence on centralized AI services like Claude, with some users spending thousands monthly on tokens. This dependency creates vulnerability to price increases and service disruptions. Jake advocates for local AI deployment using models like DeepSeek R1, running on personal hardware to maintain control and privacy. The shift toward continuous learning models will fundamentally change the AI landscape, making personal data harvesting even more valuable and raising urgent questions about compensation and consent for training data contribution.5. High-Quality Training Data Is Becoming the Primary AI Bottleneck: Stewart argues that AI development is now limited more by high-quality training data than by compute power. The industry has exhausted easily accessible internet data and body-shop-style data labeling. Companies are now using specialized boutique services with techniques like head-mounted cameras for live-streaming world model training. This scarcity is subtly driving price increases across AI services and will fundamentally reshape the economics of AI development, with implications for who controls these increasingly powerful systems.6. Urbit Offers a Foundation for Trustworthy Computing: Jake positions Urbit as essential infrastructure for the AI age because its 30,000-line codebase (versus Unix's three million lines) can be understood by individual humans. Its deterministic, purely functional, and strictly typed design aims for eventual ossification—software that doesn't require constant security patches. This "tiny and diamond perfect" approach addresses the fundamental insecurity of systems requiring monthly vulnerability patches. In an era of AI agents and potential prompt injection attacks, having verifiable, comprehensible computing infrastructure becomes existentially important rather than merely desirable.7. Nockchain Creates a Global Repository of Provable Truth: Jake's vision for Nockchain combines ZK proofs with blockchain technology to create a globally available "truth repository" where verified facts can be programmatically accessed together. This enables smart contracts or programs gated on combinations of proven facts—such as temperature readings from secure devices, supply chain events, and payment confirmations. By using Nock's abstract, simple design optimized for ZK proof generation, the system can validate complex real-world conditions without exposing underlying data, creating infrastructure for coordinating action based on verifiable private information at global scale.

February 13, 2026: AI in Drug DiscoveryIt costs $2.5 billion and up to 10 years of effort to successfully bring a new drug to market.That's an extremely high hurdle to succeed!It's no wonder why the high costs of FDA trials & the elevated rates of failure often result in small-cap drug developers declaring bankruptcy. Biotechnology is one of the stock market's riskiest sectors to invest in.But what if there was a way to change that?What if we could use technology to alleviate some of the biotech industry's deepest and most systemic risks?AI doesn't necessarily produce better drugs. Though it might be able to reduce drug development costs and timelines significantly.And if it did, that would be a game-changer for the entire industry.On today's show, my special guest Manisha Samy and I will discuss how AI-native infrastructure could vastly improve the return profiles of early-stage biotech companies.Our stock of focus will be Recursion Pharmaceuticals (Nasdaq: RXRX) who's creatively using AI to guide several programs in its development pipeline.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Gregory: I have the ability to recognize and reframe patterns.Startup failure rates have hovered around 90% for over 30 years. Gregory Shepard, Founder and CEO of Startup Science, decided to tackle this persistent challenge with a comprehensive, science-backed approach. His goal is nothing short of transformative: to reduce failure rates and create a better ecosystem for entrepreneurs.Gregory's research revealed that 47.1% of startups fail within the first 18 months, with the remaining failures often linked to poor decisions made during that critical period. “There's no industry I can think of that would be okay with 90% of the people trying to succeed failing,” he explained. “I decided to do something about it.”Startup Science offers a centralized platform where entrepreneurs, investors, mentors, and support organizations can connect and collaborate. Gregory has worked to eliminate fragmentation in the startup ecosystem by providing tools, resources, and education—all free for founders. This mission is fueled by his belief that entrepreneurship drives innovation and can create opportunities for people from all backgrounds.Gregory's commitment to democratizing entrepreneurship extends to the way he's raising funds for Startup Science. He's launched a regulated crowdfunding campaign on Wefunder, allowing anyone—not just accredited investors—to support his mission. “If somebody invests in Startup Science, you're investing into all of the startups that we're helping, which is 100,000 of them at the moment,” he said.Gregory's passion is deeply personal. Growing up in poverty, he understands the barriers many entrepreneurs face. That empathy drives his vision to create an accessible, equitable platform that empowers founders to succeed while transforming the global economy.By leveraging his scientific approach to analyzing startup success and failure, Gregory is helping entrepreneurs avoid predictable pitfalls and build sustainable businesses. His efforts could fundamentally reshape the entrepreneurial landscape, enabling innovation to thrive.To learn more or support this initiative, visit Startup Science's crowdfunding campaign. This is an opportunity to back a proven entrepreneur who's committed to doing good for the world.tl;dr:Gregory Shepard shares his mission to reduce startup failure rates with his platform, Startup Science.Startup Science connects fragmented startup ecosystem elements, offering free tools and resources for founders.Gregory discusses his scientific research on startup success and his passion for democratizing entrepreneurship.He highlights his Wefunder campaign, inviting anyone to invest in Startup Science and support entrepreneurs.Gregory explains his superpower, pattern recognition, and how it drives his success in building ecosystems.How to Develop Pattern Recognition As a SuperpowerGregory's autistic diagnosis has sharpened his ability to identify and reframe patterns; a skill he calls pattern recognition. “I have the ability to recognize and reframe patterns…startup science is a result of this,” he explained. Gregory sees connections others might overlook, enabling him to create solutions that integrate fragmented systems into cohesive ecosystems. He describes it as understanding how seemingly separate components interact, much like a solar system where the founder is the sun and other elements orbit around them.Gregory's superpower was pivotal in building and selling Affiliate Traction to eBay Enterprise Marketing Solutions. He noticed that affiliate marketing—now a cornerstone of influencer marketing—was fragmented, with disconnected tools and processes. Gregory envisioned a unified system and developed software that brought these elements together. By connecting the dots, he transformed the industry and created a successful company, later replicating this approach with other ventures.Tips for Developing Pattern Recognition:Identify the structure of a system or process by analyzing its components and relationships.Observe how elements interact within a system and look for inefficiencies or gaps.Reimagine connected systems as an ecosystem where all parts work collaboratively.Practice applying this framework in various contexts, from business to social environments.By following Gregory's example and advice, you can make pattern recognition a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Register Now!Guest ProfileGregory Shepard (he/him):Founder and CEO, Startup ScienceAbout Startup Science: Startup Science is the unified platform for the startup ecosystem, built to support founders and the organizations that help them succeed.We serve entrepreneurs, accelerators, universities, government programs, mentors, investors, and service providers in one connected system, so everyone operates with shared structure, shared data, and clearer outcomes.Entrepreneur Support Organizations work with Startup Science to provide modern program management infrastructure to run their cohorts, deliver consistent curriculum, track founder progress, and report measurable impact, without reinventing the process every cycle.Founders gain access to trusted education, tools, and ecosystem support in one place as they work with their advisors, software and service providers, and other key stakeholders to build their companies.Our mission is to bring clarity, coordination, and effectiveness to entrepreneurship at scale. Website: startupscience.ioCompany Facebook Page: facebook.com/bossstartupscienceInstagram Handle: @startupscience.io Other URL: wefunder.com/startupscienceBiographical Information: Gregory Shepard is a visionary entrepreneur and business leader who has built and sold twelve companies across BioTech, TransitTech, AdTech, and MarTech. In 2016, he sold two of his businesses in a landmark $925 million cross-brand deal, earning four private equity awards.In 2024, he published The Startup Lifecycle with Penguin Random House, receiving acclaim from global leaders and institutions. He has contributed over 100 articles to major publications, hosted Startup Science on Forbes Radio, and co-founded the Fulbright Entrepreneurship Initiative.A sought-after speaker, Shepard has delivered keynotes at TEDx, Ivy League universities, and top conferences worldwide. His personal journey—from overcoming dyslexia, neurodivergence, and poverty to becoming a serial entrepreneur—adds depth to his inspiring message.Committed to “altruistic capitalism,” he integrates social and environmental responsibility into business. His journey proves that with passion, resilience, and a willingness to challenge convention, extraordinary success is within reach.LinkedIn Profile: linkedin.com/in/gregshepardInstagram Handle: @gregshepard_ Personal Twitter Handle: @GregShepard_The Super Crowd, Inc., a public benefit corporation, is proud to have been named a finalist in the media category of the impact-focused, global Bold Awards.Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include rHealth, and SuperCrowd26 featuring PurposeBuilt100™️. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on March 17th at 1:30 PM ET/10:30 AM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including his advice on the killer experiments and CMC work that can make or break a deal. Resources: Follow Vasant Narasimhan on X: https://twitter.com/VasNarasimhanFollow Jorge Conde on X: https://x.com/JorgeCondeBio  Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.